1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics

Gβγ engages PLCβ3 at multiple sites to reorient and facilitate its activation

  1. Isaac J Fisher
  2. Kanishka Senarath
  3. Kennedy Outlaw
  4. Kaushik Muralidharan
  5. Elisabeth E Garland-Kuntz
  6. Michelle M Van Camp
  7. Thomas Komay
  8. Leon F Laskowski
  9. Asuka Inoue
  10. Evi Kostenis
  11. Nevin A Lambert
  12. Angeline M Lyon  Is a corresponding author
  1. James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, United States
  2. Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, United States
  3. Department of Biological Sciences, Purdue University, United States
  4. Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, United States
  5. Graduate School of Pharmaceutical Sciences, Tohoku University, Japan
  6. Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
  7. Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Germany
https://doi.org/10.7554/eLife.110382.3
Share this article
Cite this article
  1. Isaac J Fisher
  2. Kanishka Senarath
  3. Kennedy Outlaw
  4. Kaushik Muralidharan
  5. Elisabeth E Garland-Kuntz
  6. Michelle M Van Camp
  7. Thomas Komay
  8. Leon F Laskowski
  9. Asuka Inoue
  10. Evi Kostenis
  11. Nevin A Lambert
  12. Angeline M Lyon
(2026)
Gβγ engages PLCβ3 at multiple sites to reorient and facilitate its activation
eLife 15:RP110382.
https://doi.org/10.7554/eLife.110382.3
  2. Download BibTeX
  3. Download .RIS

eLife Assessment

This important study combines cryo-EM, biochemical, and cell-based assays to examine how Gβγ interacts with and potentiates PLCβ3. The authors present evidence for multiple Gβγ interaction surfaces and argue that Gβγ primarily enhances PLCβ3 activity after membrane recruitment rather than serving mainly as a membrane-recruitment factor. Following additional experimental support, the evidence in support of their conclusions is convincing.

https://doi.org/10.7554/eLife.110382.3.sa0

Abstract

Phospholipase C β (PLCβ) enzymes are activated by heterotrimeric G protein subunits, increasing hydrolysis of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) at the plasma membrane. All four human PLCβ isoforms (PLCβ1–4) are activated by Gαq, whereas PLCβ1–3 are activated to varying extents by Gβγ. The binding sites for Gαq on PLCβ are well established, and much has been learned about its mechanism of activation, but comparatively little is known about Gβγ-dependent activation. In this work, we used cryo-electron microscopy single-particle analysis, functional assays, and bioluminescence resonance energy transfer to investigate how Gβγ interacts with PLCβ3 in concert with activated Gαq to regulate phospholipase activity. Gβγ heterodimers bind multiple surfaces of PLCβ3 to promote activation, but alone do not recruit the enzyme to the plasma membrane. Instead, Gβγ facilitates activation by Gαq, most likely by reorienting the phospholipase catalytic site at the membrane to maximize PI(4,5)P2 hydrolysis and downstream Ca2+ release. Cell-based functional assays demonstrate that Gβγ is required for maximal PLCβ3 activation, even when Gq heterotrimers are the sole source of Gβγ. Together, these findings demonstrate that Gβγ acts as a critical positive allosteric modulator that regularly acts in concert with Gαq to activate PLCβ3 at the plasma membrane.

Introduction

Heterotrimeric G proteins regulate a wide variety of effectors downstream of G-protein-coupled receptors (GPCRs). One family of effector enzymes are the phospholipase Cβ (PLCβ) enzymes. The four PLCβ isoforms (PLCβ1–4) cleave phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) to inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). These second messengers, in turn, increase intracellular Ca2+ and activate protein kinase C (PKC). All PLCβ isoforms are activated by direct binding of Gαq, released by Gq-coupled receptors. PLCβ2 and PLCβ3 are also stimulated by binding of Gβγ heterodimers, released by Gi-coupled receptors (Smrcka and Sternweis, 1993; Kadamur and Ross, 2013).

PLCβs share four core domains with other PLC enzymes, including a pleckstrin homology (PH) domain, four EF hands, a catalytic triose phosphate isomerase (TIM) barrel split by a regulatory linker (X–Y linker) into X and Y subdomains, and a C2 domain. The PLCβ subfamily is defined by its unique proximal and distal C-terminal domains (CTDs) that follow the C2 domain. The proximal CTD (pCTD) includes the autoinhibitory Hα2′ helix, which is displaced when Gαq binds (Lyon et al., 2011), and the distal CTD (dCTD), which contributes to membrane binding and contains a second functionally critical Gαq binding site (Lyon et al., 2013). The mechanism by which Gαq binds to and activates PLCβ has been well characterized through functional and structural studies (Lyon et al., 2011; Waldo et al., 2010; Lyon et al., 2013; Senarath et al., 2025), but the mechanism by which Gβγ activates PLCβ is much less clear.

The Gβγ heterodimer has no intrinsic enzymatic activity yet regulates a wide variety of effector enzymes via membrane recruitment and/or allostery (Smrcka, 2008; Smrcka and Fisher, 2019). Prior studies of Gβγ regulation of PLCβ identified two potential, non-overlapping binding sites for Gβγ. The first was the PH domain, which serves primarily as a protein–protein interaction site in the PLCβ subfamily (Jezyk et al., 2006; Illenberger et al., 2003). The PH domain is required for Gβγ stimulation of PLCβ, and chimeras of PLCδ that contained the PH domain of PLCβ gained sensitivity to the G protein subunit (Wang et al., 2000). The second Gβγ binding site was mapped to a helix in the Y subdomain of the TIM barrel. Peptides corresponding to this region blocked Gβγ activation of PLCβ and crosslinked to Gβγ (Bonacci et al., 2005; Sankaran et al., 1998). However, Gβγ binding to this site appeared to preclude the PLCβ active site from engaging the membrane for PI(4,5)P2 hydrolysis. The mechanism of Gβγ-dependent activation is further complicated by reports that, in cells, the process requires prior or coincident activation by Gαq (Pfeil et al., 2020; Brands et al., 2024; Gao et al., 2025).

Recent structural work has shed light on how Gβγ interacts with PLCβ. Cryo-electron microscopy (cryo-EM) reconstructions of Gβγ and PLCβ on liposomes and nanodiscs showed two Gβγ molecules bound to one PLCβ3, one to the PH domain and one to the EF hand domain (Falzone and MacKinnon, 2023). The latter domain had not previously been implicated in Gβγ-dependent activation. Gβγ binding did not induce conformational changes within the lipase, and despite its proximity to a lipid bilayer, PLCβ3 remained in its autoinhibited conformation; the active site remained occluded by the X–Y linker and inhibitory interactions between the Hα2′ helix and the catalytic core persisted. Because no allosteric changes in the lipase were observed, a model was proposed in which Gβγ activates PLCβ3 by recruiting it to and orienting it at the plasma membrane (Falzone and MacKinnon, 2023). Consistent with this idea, the same study demonstrated Gβγ-dependent partitioning of PLCβ3 to a lipid bilayer (Falzone and MacKinnon, 2023), although several prior studies using purified components did not show Gβγ-dependent recruitment of the lipase to membranes (Romoser et al., 1996; Runnels et al., 1996; Runnels and Scarlata, 1998). However, the Gβγ–PLCβ3 interface(s) responsible for activation in the cellular environment are unknown. Finally, it is also unclear if G protein activation liberates sufficient free Gβγ to recruit PLCβ3 in cells.

Here, we investigate the mechanism by which Gβγ binding to PLCβ3 increases lipase activity using crosslinking, cryo-EM single particle analysis (SPA), and functional assays in living cells. We report cryo-EM reconstructions of Gβγ–PLCβ3 that reveal a third binding site for Gβγ involving the PH, EF hand, and C2 domains. We show that all three structurally determined interfaces contribute to Gβγ-dependent activation in cells. Notably, we find that free Gβγ does not promote recruitment of PLCβ3 to the plasma membrane, and that membrane-tethered PLCβ3 can still be activated by Gβγ. Thus, Gβγ binds to multiple sites on the lipase to further stimulate PI(4,5)P2 hydrolysis concomitant with activation of PLCβ3 by Gαq, most likely by orienting the enzyme at the plasma membrane. We propose that Gβγ is best understood as a critical positive allosteric modulator of PLCβ3, as opposed to a bona fide activator in cells.

Results

Cryo-EM reconstructions of Gβγ–PLCβ3 complexes in solution

We first attempted to determine the solution structure of a soluble Gβγ–PLCβ3 complex, in which the prenylated Gγ C68 is mutated to serine (Gβγ C68S; Casey, 1994), eliminating the need for lipids and/or detergents. Complexes of Gβγ C68S–PLCβ3 could be isolated by size exclusion chromatography (SEC) but were too unstable for structural determination, in agreement with previous studies (Falzone and MacKinnon, 2023). We turned to crosslinking to isolate a stable complex (Kadamur and Ross, 2016). Solvent-exposed cysteines in the lipase (human PLCβ3 residues 193, 221, 358, 516, 824, and 834) were mutated to serines in the background of PLCβ3 Δ892, a C-terminal truncation which lacks the distal CTD yet retains robust activation by Gβγ (Lee et al., 1993b; Banno et al., 1994; Fisher et al., 2020). Given the evidence that Gβγ binds to the PH domain, an E60C mutation was installed in the PH domain (PLCβ3 Δ892 PHcys) to facilitate crosslinking with Gβγ C68S (Gβ1 contains fourteen cysteines, with C204 and C271 solvent-exposed, and Gγ2 contains two cysteines with only C68 solvent-exposed). As a control, C516 was retained in the X–Y linker (PLCβ3 Δ892 XYcys). Neither variant underwent self-crosslinking, in contrast to PLCβ3 Δ892 which retains the endogenous cysteines. Only PLCβ3 Δ892 PHcys crosslinked efficiently to Gβγ C68S (Figure 1, Figure 1—figure supplement 1). Bismaleimidoethane (BMOE), an 8 Å crosslinker, had a crosslinking efficiency of >50%, and a 1:1 complex was observed with PLCβ3 Δ892 PHcys, consistent with a persistent and specific interaction (Figure 1, Figure 1—figure supplement 1b). To confirm the BMOE-crosslinked Gβγ–PLCβ3 Δ892 PHcys complex was functional, crosslinking was repeated using wild-type Gβγ and PLCβ3 Δ892 PHcys, resulting in ~threefold greater activity than the reaction without the crosslinker (Figure 1—figure supplement 1c). Similar results were also obtained with the 14.7 Å BM(PEG)2 crosslinker. The crosslinked Gβγ–PLCβ3 Δ892 PHcys complexes were purified using SEC and subjected to cryo-EM SPA. Two reconstructions were independently refined to 4 Å and 7 Å resolution in the BMOE data set (Figure 1, Figure 1—figure supplements 2–5, Supplementary file 1a, Table 1), and one 4.4 Å reconstruction in the BM(PEG)2 data set (Figure 1—figure supplements 4 and 5, Supplementary file 1a, Table 1).

Figure 1 with 5 supplements see all
Download asset Open asset
Cryo-EM reconstruction of the Gβγ–PLCβ3 Δ892-PHcys complex.

(A) Domain diagram of human PLCβ3, with numbers above corresponding to domain boundaries. PLCβ3 is regulated by the X–Y linker (hot pink), proximal C-terminal domain (pCTD, cyan), and distal CTD (purple). The CTDs are connected by the unconserved CTD linker. (B) Cryo-EM density map and (C) structure of the 4 Å Gβγ–Δ892-PHcys complex crosslinked with BMOE, with PLCβ3 colored as in 1 A, Gβ in blue, and Gγ in red.

Figure 1—source data 1

Annotated SDS-PAGE gels described in Figure 1.

https://cdn.elifesciences.org/articles/110382/elife-110382-fig1-data1-v1.zip
Figure 1—source data 2

Original, unannotated SDS-PAGE gels.

https://cdn.elifesciences.org/articles/110382/elife-110382-fig1-data2-v1.zip
Table 1
Cryo-EM data collection, refinement, and validation statistics.
Gβγ-PLCβ3
BMOE (4.1 Å)		Gβγ-PLCβ3-BMOE (7.0 Å)Gβγ-PLCβ3 BMPEG
Data collection and processing
Grids
Vitrification Method
Microscope
Magnification		Cu Quantifoil
FEI Vitrobot
Titan Krios
81000		Cu Quantifoil
FEI Vitrobot
Titan Krios
81000		Cu Quantifoil
FEI Vitrobot
Titan Krios
81000
Voltage (kV)
Detector		300
K3		300
K3		300
K3
Electron exposure (e–/Å2)53.6953.6953.69
Defocus range (μm)0.5–2.00.5–2.00.5–2.0
Pixel size (Å)
Frames		0.539
40		0.539
40		0.539
40
Symmetry
Micrographs		C1C1C1
Initial particle images (no.)1,248,9531,248,953579,743
Final particle images (no.)92,77765,306142,175
Map resolution (Å)
FSC threshold		4.06
0.143		6.77
0.143		4.40
0.143
Refinement
Initial model used (PDB code)4GNK (PLCβ3) 1GP2 (Gβ1γ2)4GNK (PLCβ3) 1GP2 (Gβ1γ2)4GNK (PLCβ3) 1GP2 (Gβ1γ2)
Model resolution (Å)
FSC threshold		4.06
0.143		6.77
0.143		4.40
0.143
Model resolution range (Å)3.4–7.07–10.74–10.7
Model composition
Non-hydrogen atoms
Protein residues
Ligands		8,913
1,125
8		8,896
1,125
0		8,967
1134
0
B factors (Å2)
Protein
Ligand		74.40
79.08		45.30
0		55.51
0
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)		0.003
0.474		0.002
0.542		0.003
0.519
Validation
MolProbity score
Clashscore
Poor rotamers (%)		1.97
6.37
1.64		2.61
11.34
4.71		2.98
40.75
3.35
Ramachandran plot
Favored (%)
Allowed (%)
Disallowed (%)		92.9
6.92
0.18		90.75
9.25
0		91.80
8.02
0.18

In all crosslinked Gβγ–PLCβ3 Δ892 PHcys complexes, Gβγ engages PLCβ3 via a surface formed primarily by the PH and EF1/2 domains that differs from the two interfaces observed previously (Figure 1—figure supplements 3–5; Falzone and MacKinnon, 2023). The relative orientation and local resolution of Gβγ with respect to PLCβ3 varies in each case, suggesting the interface is conformationally heterogeneous, most likely due to the absence of a membrane (Figure 1—figure supplements 2–5). Even though all the cysteines in Gβ are retained, and both Gβ C271 and C204 are in the ‘hotspot’ interaction surface of Gβγ, only a single crosslink between PLCβ3 E60C and Gβ Cys271 is observed (Figure 1—figure supplements 1 and 3). In the crosslinked Gβγ–PLCβ3 reconstructions reported, Gβ C204 is ~25 Å from PLCβ3 E60, well beyond the range of either BMOE or BM(PEG)2. There are also no solvent-exposed cysteines in Gβγ at the EF hand binding site within ~45 Å of PLCβ3 E60. This is consistent with a specific, persistent interaction that results in the crosslink between Gβ 271 and PLCβ3 E60C. Indeed, density for the crosslinker is observed in the 4 Å BMOE reconstruction, and the orientation of Gβγ and PLCβ3 in the 7 Å BMOE and BM(PEG)2 reconstructions are also consistent with crosslinking via this site.

In the crosslinked complexes, as in the prior structures, PLCβ3 Δ892 PHcys is autoinhibited by its X–Y linker and pCTD (Figure 1; Lyon et al., 2011; Waldo et al., 2010; Jezyk et al., 2006; Falzone and MacKinnon, 2023; Lyon and Tesmer, 2013). This is consistent with previous reports demonstrating the membrane is essential for regulation by Gβγ and that its activation mechanism is independent of the PLCβ CTDs (Kadamur and Ross, 2013). The crosslinked Gβγ is situated such that it allows simultaneous binding of Gαq to PLCβ with the C-terminal helix of Gγ nearly in the same plane as the phospholipase active site. Thus, the solution reconstruction may represent a membrane-localized complex, but not a catalytically active state.

In the 4 Å reconstruction (Figures 1 and 2A), the Gβγ–PLCβ3 Δ892 PHcys interface buries ~1400 Å2 surface area. This is more extensive than the Gβγ-PH domain or Gβγ-EF hand interfaces, which bury ~800 Å2 and ~1100 Å2 respectively (Figure 2B and C; Falzone and MacKinnon, 2023). The primary Gβγ interface is formed by residues on the side of the WD40 toroid, rather than its face, which is the typical effector interface (Figure 2, Figure 2—figure supplements 1–3). Nevertheless, the crosslinked Gβγ–PLCβ3 Δ892-PHcys interface includes several residues known to be critical for enzyme activation, and the specific interactions differ from the other reported Gβγ–PLCβ3 interfaces (Figure 2—figure supplements 1 and 2). In the BMOE complex, Gβ D228 interacts with R199 and K183 in PLCβ3, whereas in the Gβγ–PLCβ3–Gβγ reconstruction Gβ D228 interacts with R24 or K238 in the PH domain and EF hand interfaces, respectively (Figure 2A–C). In our Gβγ–PLCβ3 Δ892 PHcys structure, Gβ K301 and R304 on blade 6 make electrostatic interactions with PLCβ3 R741 and E34, respectively (Figure 2A). These interactions were not reported in the liposome-bound Gβγ–PLCβ–Gβγ complex (Falzone and MacKinnon, 2023) and provide a structural explanation for observations reported over thirty years ago by Neer and coworkers on the importance of Gβ blades 6 and 7 in lipase activation (Panchenko et al., 1998; Drin and Scarlata, 2007). On the other hand, Gβ W99, a critical residue for effector activation including PLCβ2 (Ford et al., 1998), does not interact with the lipase in the crosslinked complexes, but does interact in the Gβγ–PLCβ3–Gβγ complex. Taken together with previous structural findings, our results suggest that Gβγ can bind to PLCβ3 at several sites with modest affinity.

Figure 2 with 4 supplements see all
Download asset Open asset
Functional analysis of Gβγ–PLCβ3 interfaces: IP accumulation.

Comparison of the (A) Gβγ–Δ892-PHcys interface observed in this study, and the previously reported (B) Gβγ–PLCβ3 PH and (C) Gβγ–PLCβ3 EF hand interfaces (PDB ID: 8EMW) (Falzone and MacKinnon, 2023). Proteins are colored as in Figure 1. Residues in PLCβ3 and Gβγ shown as balls and sticks were mutated, and their basal and G protein-dependent activities quantified in a cell-based [3H]-IPx accumulation assay. Basal and Gαq-dependent activation was used as a control to confirm the PLCβ3 variants were properly folded. Changes in activity are not due to differences in expression (Figure 2—figure supplement 4). The activities of the PLCβ3 mutants in the (D) BMOE-crosslinked Gβγ–Δ892-PHcys interface and (E) Gβγ–PLCβ3 PH/EF hand interfaces were measured. Mutations to the Gβ1 subunit were similarly assessed for (F) the crosslinked Gβγ–Δ892-PHcys interface and (G) the Gβγ–PH/EF hand interfaces. All assays were performed in triplicate from at least three independent transfections, and data shown are mean ± SEM. Data in D and E were analyzed using a two-way ANOVA followed by Dunnett’s post-hoc multiple comparisons test, comparing the basal activity of each PLCβ3 variant to its activation Gβγ or Gαq. ***, p<0.0005, **, p<0.005, *, p<0.05. Data in F and G were analyzed using a one-way ANOVA, followed by Dunnett’s post-hoc multiple comparisons test, comparing the Gβγ-stimulated activity of each PLCβ3 mutant to that of wild-type PLCβ3. ***, p<0.0005, **, p<0.005, *, p<0.05.

Functional analysis of Gβγ–PLCβ3 interfaces: IP accumulation

To assess the functional relevance of the Gβγ–PLCβ3 interfaces observed in cryo-EM reconstructions (Figure 2), mutations were introduced to maximally disrupt the three observed interfaces by changing amino acid size and/or charge. The activity of the mutants was assessed using a cell-based inositol phosphate (IP) accumulation assay in COS7 cells, where PLCβ3 activity is increased by the overexpression of either Gβγ or Gαq. Mutation of residues in PLCβ3 or Gβ1 at any one of the three observed interfaces decreased Gβγ-dependent activation of the lipase (Figure 2D–G). PLCβ3 mutants with decreased responsiveness to Gβγ are most likely impaired in binding the Gβγ heterodimer, as their expression and activation by Gαq were minimally altered (Figure 2D–G; Figure 2—figure supplement 4). PLCβ3 K183E and R199A, which eliminate electrostatic interactions with Gβ E226 and D228 in the crosslinked complexes, have threefold lower Gβγ-stimulated activity, while PLCβ3 R199E was not responsive to Gβγ (Figure 2D and E). PLCβ3 R24E, L40G, and R185L, which disrupt interactions with Gβγ observed in the liposome-tethered reconstructions, also showed threefold lower activation (Figure 2E; Falzone and MacKinnon, 2023; Ford et al., 1998). Gβ D228R, which interacts with PLCβ3 in all reconstructions (Figure 2F and G; Falzone and MacKinnon, 2023; Li et al., 1998), decreased activation of PLCβ3 by ~20-fold, which cannot be fully attributed to reduced protein expression (Figure 2—figure supplement 4). Mutations in Gβ blades 6 and 7, GβK301E and R304D, also decreased PLCβ3 activation, in agreement with previous reports (Lee et al., 1993b; Figure 2F and G).

Functional analysis of Gβγ–PLCβ3 interfaces: PLCβ3 interaction with Gβγ

Under physiological conditions, PLCβ3 is activated in response to GPCR stimulation that activates Gq heterotrimers, rather than overexpression of Gαq or Gβγ as in the previous experimental setting. To assess the functional significance of the three Gβγ–PLCβ3 interfaces downstream of receptor activation, we developed a BRET assay to monitor Gβγ binding to PLCβ3 in live cells in real time. This effort was complicated by the fact that a large fraction of PLCβ3 is cytosolic, whereas Gβγ is anchored to the plasma membrane. Because of this, recruitment of PLCβ3 to the plasma membrane by any means (e.g. binding to Gαq·GTP) would cause an increase in bystander BRET between PLCβ3 and Gβγ that would sum with BRET due to direct interactions between the two. To eliminate this confound, we anchored HiBit-labeled PLCβ3 to the plasma membrane with a C-terminal CAAX motif, which prevents increases in bystander BRET due to translocation and thus isolates signals due to interactions between Venus-Gβγ and the lipase at the plasma membrane. Activation of angiotensin AT1 receptors induced a rapid increase in BRET between HiBit-PLCβ3-CAAX (coexpressed with LgBit and Gαq) and Venus-Gβγ (Figure 3A). This signal was completely blocked by membrane-localized GRK3ct, which binds and sequesters free Gβγ, and enhanced by membrane-localized GRK2RH, which binds and sequesters free Gαq·GTP (Figure 3A). The latter observation is complementary to our previous finding that sequestering Gβγ enhances Gαq binding to PLCβ3; both findings suggest that PLCβ3 competes with G protein subunits for binding to the complementary G protein subunits (Senarath et al., 2025).

Figure 3 with 2 supplements see all
Download asset Open asset
Functional analysis of Gβγ–PLCβ3 interfaces: interaction with G proteins and PI(4,5)P2 hydrolysis.

(A) BRET between membrane-anchored HiBit-PLCβ3-CAAX and Venus-Gβγ increases after activation of AT1 with angiotensin II (AngII; 1 μM). Signals are blocked by membrane-tethered GRK3ct (GRK3ct) and enhanced by membrane-tethered GRK2RH, which sequester free Gβγ and Gαq-GTP, respectively. Traces are the average of twenty replicates from five independent experiments. (B) AngII-induced changes in BRET between HiBit-PLCβ3-CAAX and Venus-Gβγ (ΔBRET) for sixteen mutants across the three Gβγ–PLCβ3 interfaces; most mutants showed significant changes (denoted by an asterisk) in their interactions with Venus-Gβγ compared to wild-type HiBit-PLCβ3-CAAX. (C) In ΔPLC cells, expression of HiBit-PLCβ3 (without LgBit) reconstitutes AngII-induced PI(4,5)P2 hydrolysis, as indicated by bystander BRET between Nluc-PH and mem-link-Venus (mem-Venus). Traces are the average of sixteen replicates from four independent experiments. (D) AngII-induced PI(4,5)P2 hydrolysis (ΔBRET) for the same HiBit-PLCβ3 mutants as panel B; most mutants showed significant changes in PI(4,5)P2 hydrolysis (denoted by asterisks). (E) In HEK cells, BRET between HiBit-PLCβ3 and Gαq-Venus increases after activation of AT1. Traces are the average of twelve replicates from three independent experiments. (F) BRET between the same HiBit-PLCβ3 mutants as panel B and Gαq-Venus; none of the mutants showed significant changes compared to wild-type HiBit-PLCβ3. For B, D, and F, all mutants were compared to wild-type HiBit-PLCβ3-CAAX or HiBit-PLCβ3 using one-way ANOVA with Dunnett’s post-hoc comparisons; data points represent averages from independent experiments (n=3–11) performed in quadruplicate. For all mutants, * p<0.05 and individual p values are given in Supplementary file 1b-e.

We next used this interaction assay to test a series of sixteen HiBit-PLCβ3-CAAX mutants designed to disrupt the three structurally determined Gβγ–PLCβ3 interfaces by altering amino acid size and/or charge. Mutations in the two interfaces observed in the liposome-tethered reconstructions significantly reduced agonist-induced BRET between Venus-Gβγ and HiBit-PLCβ3-CAAX (Figure 3B). For example, L40E in the PH domain interface and R185E in the EF hand interface almost completely abolished receptor-mediated signals (Figure 3B). In the crosslinked interface, R199E essentially eliminated the BRET response. The K183E mutant had impaired activation by Gβγ in our IP accumulation assays, but did not significantly reduce agonist-induced BRET signal. Surprisingly, mutations at residues D167 in the PH domain interface and R215 in the EF hand interface significantly increased receptor-mediated interaction between Venus-Gβγ and HiBit-PLCβ3-CAAX (Figure 3B). Overall, these results support the conclusion that the functional defects observed in our IP accumulation assays reflect loss of Gβγ binding.

Notably, the almost complete loss of agonist-induced BRET signals after disruption of the PH or EF hand interfaces suggests that, when attached to a membrane, Gβγ dimers might cooperate to bind at both sites. This is consistent with the relatively weak binding of Gβγ in vitro and difficulties isolating stable Gβγ–PLCβ3 complexes in solution. We then asked if cooperative binding of G protein subunits might extend to Gαq, i.e. if binding of Gαq promotes binding of Gβγ. Using the same Gβγ–PLCβ3 interaction assay, we first compared signals downstream of AT1, which activates both Gq and Gi/o heterotrimers, to those downstream of the dopamine D2 receptor (D2R), which activates only Gi/o heterotrimers. D2R-mediated signals were detectable, but significantly smaller than AT1-mediated signals (Figure 3—figure supplement 1A). Under the same conditions, D2R liberated more free Venus-Gβγ than AT1 when detected by the membrane-linked GRK3ct-Nluc sensor (Figure 3—figure supplement 1B), suggesting that the presence of Gαq·GTP promotes Gβγ binding to HiBit-PLCβ3-CAAX. To further test this idea, we constructed HiBit-PLCβ3-CAAX mutants with disrupted Gαq binding to the proximal CTD (HiBit-PLCβ3-CAAX-LE) or the distal CTD (HiBit-PLCβ3-CAAX-EEE) (Senarath et al., 2025). Interaction of both mutants with Venus-Gβγ was significantly impaired compared to wild-type HiBit-PLCβ3-CAAX (Figure 3—figure supplement 1C). These results suggest that Gβγ binding to the PH and EF interfaces is facilitated by binding of Gαq·GTP.

Functional analysis of Gβγ–PLCβ3 interfaces: receptor-evoked PI(4,5)P2 hydrolysis

To better understand the role of Gβγ binding to different interfaces in receptor-mediated PLCβ3 activation, we carried out PI(4,5)P2 hydrolysis assays based on the binding of the PH domain of PLCδ to PI(4,5)P2 at the plasma membrane. PI(4,5)P2 hydrolysis releases Nluc-PH-PLCδ (Nluc-PH) into the cytosol, which is detected as a loss of bystander BRET to a marker on the plasma membrane (mem-Venus; Figure 3C). We first established that endogenous Gβγ contributes to activation of endogenous PLCβ3 (the only PLCβ isoform expressed at significant levels in HEK 293 cells) downstream of AT1 receptors. Accordingly, PI(4,5)P2 hydrolysis after activation of AT1 was inhibited by GRK3ct (Figure 3—figure supplement 2A, B). Because AT1 receptors activate both Gq and Gi/o heterotrimers, we were interested to know the source of the Gβγ contributing to PLCβ3 activation. We found that pertussis toxin (PTX) partially blocked AT1-mediated PI(4,5)P2 hydrolysis, consistent with Gβγ from Gi/o heterotrimers stimulating lipase activity (Figure 3—figure supplement 2A, B). However, GRK3ct still inhibited PI(4,5)P2 hydrolysis when PTX was present, indicating Gβγ from Gq heterotrimers contributes as well (Figure 3—figure supplement 2A, B).

Next, we reconstituted the same PI(4,5)P2 hydrolysis assay in genome-edited HEK 293 cells lacking endogenous PLCβ proteins (ΔPLC cells) by expressing wild-type (wt) or mutant HiBit-PLCβ3. PI(4,5)P2 hydrolysis mediated by expressed HiBit-PLCβ3 was inhibited by GRK3ct to roughly the same extent as that mediated by endogenous PLCβ3 in parental cells (Figure 3C). Notably, PI(4,5)P2 hydrolysis under these conditions was completely blocked by GRK2RH, consistent with the idea that activation of PLCβ3 by Gβγ in cells requires Gαq·GTP (Figure 3C). PI(4,5)P2 hydrolysis signals mediated by HiBit-PLCβ3 variants with impaired Gβγ binding were significantly smaller than signals mediated by wt HiBit-PLCβ3 (Figure 3D). Among the most defective variants were the L40E PH domain and R185E EF hand mutants, the latter supporting very modest PI(4,5)P2 hydrolysis comparable to that remaining when Gβγ is sequestered by GRK3ct (Figure 3D). Consistent with the Gβγ sequestration, these mutants were still significantly impaired in the presence of PTX (Figure 3—figure supplement 2C, D). R199A and K183E, the interface mutants in the crosslinked conplex, also had significantly reduced agonist-induced PI(4,5)P2 hydrolysis (Figure 3D). Conversely, in agreement with our Gβγ interaction results, the D167A mutant in the PH domain interface significantly increased receptor-mediated PI(4,5)P2 hydrolysis (Figure 3D). Overall, there was an excellent correlation between Gβγ binding and PI(4,5)P2 hydrolysis across the 16 mutants we tested, and good agreement with our IP accumulation assays. There were no significant differences between wt HiBit-PLCβ3 and any mutant with respect to association with Gαq-Venus (Figure 3E and F) or expression level (Supplementary file 1a), ruling out indirect effects on Gαq binding or protein stability. These findings indicate that all three of the structurally resolved Gβγ–PLCβ3 interfaces contribute to activation of PLCβ3 downstream of AT1 receptors.

Gβγ facilitates activation of membrane-anchored PLCβ3

PLCβ3 is not tightly anchored to the plasma membrane, and Gβγ has been proposed to increase lipase activity by recruiting the holoenzyme to the membrane. We previously found that AT1 activation results in recruitment of PLCβ3 to the plasma membrane, but concluded that this was primarily mediated by binding to Gαq·GTP (Senarath et al., 2025). To test the possibility that Gβγ binding contributes to membrane recruitment of PLCβ3, we used our previously established bystander BRET recruitment assay (Figure 4A). We found that none of the mutations that inhibited Venus-Gβγ binding and PI(4,5)P2 hydrolysis significantly impaired recruitment of HiBit-PLCβ3 to the plasma membrane (Figure 4B), indicating that recruitment depends entirely on binding to Gαq·GTP (Senarath et al., 2025). As an alternative test of this hypothesis, we asked if Gβγ increased the activity of HiBit-PLCβ3-CAAX, which is tightly anchored to the plasma membrane and therefore not subject to translocation from the cytosol. We found that GRK3ct was effective at inhibiting PI(4,5)P2 hydrolysis by HiBit-PLCβ3-CAAX (Figure 4C), similar to its effect on PI(4,5)P2 hydrolysis mediated by endogenous PLCβ or HiBit-PLCβ3. Likewise, mutations in HiBit-PLCβ3-CAAX that impaired Gβγ binding also impaired PI(4,5)P2 hydrolysis (Figure 4C and D). Taken together, these results suggest that Gβγ does not facilitate PLCβ3 activation by recruiting the lipase to the plasma membrane, but rather enhances the catalytic activity of Gαq-bound PLCβ3 through a distinct allosteric mechanism at the membrane.

Figure 4
Download asset Open asset
Gβγ facilitation of PLCβ3 activation does not reflect membrane recruitment.

(A) Activation of AT1 induces translocation of HiBit-PLCβ3 to the plasma membrane as indicated by bystander BRET between HiBit-PLCβ3 and mem-Venus. Traces are the average of twelve replicates from three independent experiments. (B) BRET between the same HiBit-PLCβ3 mutants as Figure 3 and mem-Venus; none of the mutants showed a significant defect in membrane translocation compared to wild-type HiBit-PLCβ3. Individual p values are given Supplementary file 1f. (C) In ΔPLC cells, expression of HiBit-PLCβ3-CAAX reconstitutes AngII-induced PI(4,5)P2 hydrolysis, indicated by bystander BRET between Nluc-PH and mem-Venus. Signals are inhibited by membrane-tethered GRK3ct, which sequesters free Gβγ. Traces are the average of twenty-eight replicates from seven independent experiments. (D) PLCβ3-CAAX variants shown to be defective with respect to Gβγ binding are also defective with respect to PI(4,5)P2 hydrolysis. For B, all mutants were compared to wild-type HiBit-PLCβ3, and for D all mutants were compared to +GRK3 ct RQ (a mutant defective in binding Gαq·GTP), using one-way ANOVA with Dunnett’s post-hoc comparisons; data points represent averages from independent experiments (n=3 or 7) performed in quadruplicate. For all mutants, * P<0.05 and individual p values are given in Supplementary file 1f and g.

Discussion

PLCβ enzymes have critical roles in numerous processes, from cardiovascular and vascular smooth muscle function to opioid sensitivity (Atef and Anand-Srivastava, 2016; Calizo et al., 2020; Filtz et al., 2009; Mathews et al., 2008; Xie et al., 1999). PLCβ basal activity is tightly controlled, and direct binding of Gαq and Gβγ subunits, released downstream of Gq- and Gi/o-coupled receptors, is essential for robust PI(4,5)P2 hydrolysis (Kadamur and Ross, 2013). The mechanisms by which Gαq interacts with PLCβ to increase lipase activity have been well-characterized through structural and functional studies (Kadamur and Ross, 2013; Lyon et al., 2011; Lyon et al., 2013; Senarath et al., 2025; Waldo et al., 1996). Much less is known about how Gβγ binds to and activates PLCβ1–3. Prior studies established roles for the PH domain and, to a lesser extent, the TIM barrel in Gβγ-dependent activation (Wang et al., 2000; Bonacci et al., 2005; Sankaran et al., 1998; Romoser et al., 1996; Kadamur and Ross, 2016; Charpentier et al., 2014). The cryo-EM structure of a liposome-tethered Gβγ–PLCβ3 complex confirmed that Gβγ bound directly to the PH domain, and surprisingly, that a second Gβγ molecule bound to the EF hands (Falzone and MacKinnon, 2023). However, the functional relevance of both binding sites remained unclear. Moreover, binding of Gβγ also failed to induce conformational changes in the lipase necessary for activation, despite the proximity to a membrane surface. A model was proposed in which Gβγ activates PLCβ3 via membrane recruitment and orientation (Falzone and MacKinnon, 2023). However, this model contradicted previous studies showing Gβγ did not recruit PLCβ to the plasma membrane (Bonacci et al., 2005; Romoser et al., 1996; Kadamur and Ross, 2016; Fisher et al., 2020; Feng et al., 2005; Han et al., 2011; Barr et al., 2000). Interpreting membrane recruitment studies is complicated by the use of proteoliposome sedimentation assays, which can be confounded by aggregation of proteins on the liposome surface (Zhao et al., 2012), heterogeneity in size, composition, and curvature of the liposomes (Veit et al., 2022), their propensity to phase separate (Škrabálková et al., 2024), and difficulties in quantifying free versus liposome-bound protein (Jose et al., 2020). Thus, the question of mechanism remained unsettled.

In this study, we used cryo-EM, activity and signaling assays, and BRET to validate Gβγ–PLCβ3 interactions, assess their contribution to PI(4,5)P2 hydrolysis, and establish whether Gβγ activates PLCβ3 via membrane recruitment. Using cryo-EM, we identified a third Gβγ binding site on the PLCβ3 PH domain and confirmed all structurally determined Gβγ binding sites are necessary for maximum G protein-stimulated activity (Figures 1—3). Multiple Gβγ subunits binding to a single effector is not without precedent, as two Gβγ molecules must bind to non-overlapping sites on phosphatidylinositol 3-kinase γ (PI3Kγ) for maximum membrane recruitment and activation (Figure 2—figure supplement 1; Chen et al., 2024; Rathinaswamy et al., 2021). The structures of Gβγ–PLCβ3 complexes all tether the lipase to the membrane (Figure 5), but it is unlikely that all three sites could be occupied simultaneously during catalysis. In the crosslinked Gβγ–PLCβ3 complex, the orientation of Gβγ is unlikely to be compatible with the binding of the lipase active site to the membrane (Figures 1 and 5A). We propose this reflects an encounter complex, or pre-activation state, given the specificity and efficiency of the crosslinking reaction (Figure 1—figure supplement 1). In contrast, both Gγ subunits in the liposome-tethered Gβγ–PLCβ3–Gβγ complex and the lipase active site can simultaneously interact with the membrane (Figure 5B). Our observation that disruption of either of these sites can severely compromise Gβγ binding suggests a degree of cooperativity between these sites.

Figure 5
Download asset Open asset
G protein–PLCβ3 complexes at the membrane.

(A) The crosslinked Gβγ–PLCβ3 complex is compatible with membrane localization, but not lipase activity. PLCβ3 is shown as a surface, and Gβγ in ribbon. Proteins are colored as in Figure 1A. (B) The liposome-tethered Gβγ–PLCβ3 complex would allow the PLCβ3 active site to interact with the membrane. (C) The crosslinked and (D) liposome-tethered complexes are compatible with Gαq·GTP binding and activation via displacement of the Hα2' helix (cyan) and engagement of the dCTD (dark gray). In both models, the dCTD binds the membrane through electrostatic interactions.

Comparisons of the predicted Gβγ binding sites in PLCβ1–4 also provide some insights into the isoform-specific differences in Gβγ-dependent activation. Of the ten residues we identified as functionally relevant across the three PLCβ3 Gβγ binding sites (Figures 2 and 3), only two are conserved in PLCβ4. The other residues are incompatible with Gβγ binding and likely explain why Gβγ does not activate this isoform (Lee et al., 1994; Lee et al., 1993a). In PLCβ1 and PLCβ2, seven of the residues identified are conserved, the exceptions being PLCβ3 R204 and R215. In PLCβ1, these residues are replaced by proline and valine, respectively, and in PLCβ2 they are asparagine and serine. Whether these differences are sufficient to explain why PLCβ1 is minimally activated by Gβγ while PLCβ2 is robustly activated remains to be established (Smrcka and Sternweis, 1993).

Previous work has shown that PLCβ3 must be preactivated, or simultaneously activated, by Gαq·GTP in cells before Gβγ binds to further increase PI(4,5)P2 hydrolysis (Pfeil et al., 2020). This is consistent with the fact that all Gβγ–PLCβ3 reconstructions are fully compatible with simultaneous binding Gαq·GTP at the membrane (Figure 5C and D). Gαq binding is essential for translocation of the lipase to the plasma membrane (Senarath et al., 2025), and mutation of any of the three structurally characterized Gβγ binding sites has no impact on lipase translocation (Figure 3). Moreover, free Gβγ released by activation of Gi/o heterotrimers does not promote translocation (Senarath et al., 2025). While Gβγ clearly does not increase lipase activity via membrane recruitment, its binding to the lipase is essential for maximum PI(4,5)P2 hydrolysis (Figure 3), even when PLCβ3 is tethered at the membrane (Figure 4). While Gβγ recruitment and reorientation of PLCβ3 at the membrane were proposed as activation mechanisms, they were not directly tested. Here, we have elucidated this mechanism, and our results demonstrate that Gβγ is a positive allosteric modulator of PLCβ3, following direct activation of the phospholipase by Gαq, as opposed to a bona fide activator. In this paradigm, Gβγ binding to the PH domain and/or EF hands optimizes the orientation of Gαq–PLCβ3 at the membrane to facilitate interfacial activation and maximize PI(4,5)P2 hydrolysis (Figure 5E).

Finally, our results show that Gβγ is surprisingly important for PLCβ3 activation by Gq heterotrimers in cells. While synergistic activation of PLCβ3 by Gαq and Gβγ is well known, this synergy is typically discussed as a mechanism of crosstalk between Gq and Gi signaling, the latter being the source of Gβγ dimers (Rebres et al., 2011; Sanchez et al., 2022). Gβγ affinity for PLCβ3 is relatively low and only Gi/o heterotrimers are thought to be expressed at high enough levels to release sufficient free Gβγ. Here we show that PI(4,5)P2 hydrolysis downstream of Gq alone is sensitive to sequestration of Gβγ dimers, consistent with a previous study in HeLa cells (Kankanamge et al., 2021), as well as mutations that disrupt Gβγ binding. Endogenous Gq heterotrimers are evidently capable of releasing sufficient free Gβγ to occupy binding sites on PLCβ3. This is most likely enabled by cooperative binding of G protein subunits to PLCβ3 at the plasma membrane.

Materials and methods

Cell culture and transfection

Request a detailed protocol

Human embryonic kidney HEK 293 cells were obtained from ATCC (CRL-1573) and used as supplied or after gene editing as described previously (Brands et al., 2024; Jang et al., 2024); ΔPLCβ1–4 (ΔPLC) cells were generated using CRISPR/Cas9 and validated as described previously (Brands et al., 2024). Cells were transfected in 6-well plates in growth medium using linear polyethyleneimine MAX (Polysciences) at a nitrogen/phosphate ratio of 20 and were used for experiments 24–48 hr later. Up to 3.0 μg of plasmid DNA was transfected in each well of a six-well plate. COS-7 cells were a gift from A.V. Smrcka and used for [3H]-IPx accumulation assays. Human cell lines have been authenticated via STR profiling, while COS-7 cells were authenticated by COI barcoding. All cell lines are negative for mycoplasma contamination.

Plasmids

SNAPf-AGTR1, HiBit-PLCβ3, HiBit-PLCβ3-CAAX, mem-link-Venus, mem-GRK3ct, mem-link-amber-GRK2RH, Nluc-PH, Gαq-Venus, CMV-LgBit, Venus-1–155-Gγ2 and Venus-156–239-Gβ1 were described previously (Senarath et al., 2025). Mutations in HiBit-PLCβ3, HiBit-PLCβ3-CAAX were made by amplifying three fragments from wild-type plasmids with the desired mutation incorporated in a primer, assembling using Gibson assembly and verifying by full plasmid sequencing. Mutations in human PLCβ3 in pFastbac1, pCMV, or pCDNA3.1 were generated using the Takara infusion site-directed mutagenesis kit (Takara) and verified by full plasmid sequencing. The same strategy was used to subclone Gβ1 and Gγ2 in pCI-Neo (Madukwe et al., 2018) and Gαq in pCDNA3.1+.

Protein expression, purification, and complex formation

Protein expression

Request a detailed protocol

PLCβ3, PLCβ3 Δ892 and variants, Gβγ, and Gβγ C68S were expressed and purified from baculovirus-infected insect cells. Baculoviruses were generated using the FastBac recombinant baculovirus system (Invitrogen/Thermo Fisher Scientific, Inc) in ESF 921 Insect Cell Culture Medium (Expression Systems)-adapted Sf9 (Spodoptera frugiperda) cells.

Purification of Gβγ and Gβγ C68S

Request a detailed protocol

High Five cells were infected with baculoviruses encoding His6-Gαi1, Gβ1, and Gγ2 (Davis et al., 2005; Kozasa and Gilman, 1995). Cells were harvested 60 hr post-infection by centrifugation at 2500 × g, frozen in liquid N2, and stored at –80 °C.

All purification steps were performed at 4 °C unless otherwise indicated. Cell pellets were thawed in 15 mL of lysis buffer 50 mM HEPES pH 8.0, 3 mM MgCl2, 10 mM β-mercaptoethanol, 0.1 mM EDTA, 100 mM NaCl, 10 μM GDP, and protease inhibitors (133 μM PMSF, 21 μg/mL TLCK, and 0.5 μg/mL TPCK) and lysed by four freeze-thaw cycles in liquid nitrogen. Lysate was diluted to 100 mL with lysis buffer and centrifuged at 100,000 × g for 30 min to isolate the membrane fraction. The membrane pellets were resuspended by dounce in 5 mL extraction buffer (50 mM HEPES pH 8.0, 3 mM MgCl2, 50 mM NaCl, 10 mM β-mercaptoethanol, 10 μM GDP, and protease inhibitors), combined, and diluted to 60 mL. Cholate was added to a final concentration of 1% and the mixture stirred for 1 hr at 4 °C to extract membrane proteins. Detergent extracts were clarified by centrifugation at 100,000 × g for 45 min. The supernatant was diluted fivefold with buffer A (50 mM HEPES pH 8.0, 3 mM MgCl2, 10 mM β-mercaptoethanol, 100 mM NaCl, 10 μM GDP, 0.5% polyoxyethylene(10) lauryl ether (C12E10), and protease inhibitors) and applied to a cOmplete His-Tag Purification Resin (Roche) column pre-equilibrated with buffer A. The column was washed with 100 mL of buffer A supplemented with 300 mM NaCl and 5 mM imidazole, then transferred to room temperature and washed with 12 mL buffer A. Gβ1γ2 subunits were released from His6-Gαi1 using six 4 mL fractions of RT buffer (buffer A supplemented with 150 mM NaCl, 5 mM imidazole, 50 mM MgCl2, 10 mM NaF, 10 μM AlCl3, and 1% cholate). Fractions were analyzed by SDS-PAGE and Coomassie staining to assess purity. Fractions containing Gβγ were pooled and applied to a MonoQ column pre-equilibrated with 20 mM HEPES, pH 8, 1 mM DTT, 50 mM NaCl, and 0.5% CHAPS, and eluted with a 50–500 mM NaCl gradient. Fractions containing purified protein were identified by SDS-PAGE, concentrated to 20–40 μM, flash frozen in liquid N2, and stored at –80 °C.

Gβγ C68S was purified as described with some modifications. Briefly, after cell lysis, the supernatant was diluted fivefold with buffer A lacking polyoxyethylene(10) lauryl ether, glass fiber-filtered, and applied to cOmplete His-Tag Purification Resin (Roche) as described. The rest of the steps were carried out as described, with the omission of cholate or CHAPS from the buffers.

Purification of PLCβ3 and variants

Request a detailed protocol

His6-PLCβ3, PLCβ3 Δ892, PLCβ3 Δ892-PHcys, and PLCβ3 Δ892-XYcys were expressed in Sf9 cells grown in S6900 II serum-free media and infected with baculovirus at an MOI of 1 (Ghosh et al., 2004). After 48 h, cells were harvested by centrifugation, frozen in liquid N2, and stored at –80 °C. Cells were rapidly thawed and lysed by four freeze-thaw cycles in liquid nitrogen in lysis buffer (20 mM HEPES, pH 8, 50 mM NaCl, 10 mM β-mercaptoethanol, 0.1 mM EDTA, 0.1 M EGTA, 133 μM PMSF, 21 μg/ml TLCK and TPCK, 0.5 μg/ml aprotinin, 0.2 μg/ml Leupeptin, 1 μg/ml Pepstatin A, 42 μg/ml Tosyl-L-Arginine Methyl Ester [TAME], 10 μg/ml Soy Bean Trypsin Inhibitor [SBTI]). Lysed cells were collected and diluted with lysis buffer and NaCl to a final concentration of 800 mM NaCl, and centrifuged at 100,000 × g for 1 hr. The supernatant was diluted fivefold with lysis buffer containing 0.5% polyoxyethylene(10) lauryl ether (C12E10) and centrifuged again at 100,000 × g for 1 hr. The supernatant was loaded onto a cOmplete His-Tag Purification Resin (Roche) column pre-equilibrated with buffer A (20 mM HEPES, pH 8, 100 mM NaCl, 10 mM β-mercaptoethanol, 0.1 mM EDTA, and 0.1 M EGTA). The column was washed with three column volumes (CVs) of buffer A, followed by 3 CVs of buffer A supplemented with 300 mM NaCl and 10 mM imidazole. The protein was eluted with 3–10 CVs of buffer A supplemented with 200 mM imidazole. Proteins were concentrated and loaded onto tandem Superdex 200 columns (10/300 GL; GE Healthcare) equilibrated with SEC buffer (20 mM HEPES pH 8, 200 mM NaCl, 2 mM DTT, 0.1 mM EDTA, and 0.1 M EGTA). Fractions containing purified protein were identified by SDS-PAGE and were pooled, concentrated, and flash frozen in liquid N2.

Crosslinking and complex isolation

Request a detailed protocol

Purified Gβγ-C68S, Gβγ, PLCβ3 Δ892, PLCβ3 Δ892-PHcys, and PLCβ3 Δ892-XYcys were buffer exchanged to remove DTT by concentrating the proteins in an Amicon Ultra 0.5 ml 30 K concentrator (Millipore-Sigma) and washing them twice with 20 mM HEPES pH 7.4, 100 mM NaCl, 0.1 mM EDTA, and 0.1 mM EGTA (and 0.5% CHAPS for Gβγ). 25 μM of the buffer-exchanged Gβγ and 25 μM PLCβ3 Δ892, PLCβ3 Δ892-PHcys, or PLCβ3 Δ892-XYcys were mixed, and crosslinking initiated by addition of 200 μM BMOE or BM(PEG)2. Reactions were incubated for 45 min at room temperature and quenched by addition of 20 mM DTT. Crosslinking of Gβγ and PLCβ 3Δ892-PHcys was completed as above but contained 0.5% CHAPS. Crosslinking was confirmed by SDS-PAGE by the presence of a band at ~135 kDa, consistent with a 1:1 stoichiometric complex (Gβ MW: 35 kDa, PLCβ3-Δ892 MW: 100.89 kDa).

Cryo-EM

Sample preparation and data collection

Request a detailed protocol

For the BMOE-crosslinked and BM(PEG)2-crosslinked Gβγ C68S–PLCβ3 Δ892-PHcys complexes, 3.5 μL of purified complex at 1 mg/mL supplemented with 0.2% CHAPS(f)~5 min before blotting was applied onto glow-discharged Quantifoil R1.2/1.3 300-mesh grids and prepared and imaged as described for PLCβ3. For the BMOE sample, micrographs were collected on a Titan Krios G1 electron microscope (FEI) equipped with a post-GIF K3 direct electron detector (Gatan) in the Purdue Life Sciences Cryo-EM Facility. A dataset containing ~4515 images was collected in super-resolution mode with a pixel size of 0.539 Å, at a defocus range of 1–3 μm using Leginon. For each movie stack, 40 frames were recorded at a frame rate of 78ms per frame and a total dose of 53.69 electrons/Å2. For the BM(PEG)2 sample, micrographs were collected on a Titan Krios G4 electron microscope (FEI) equipped with a Post-GIF K3 direct electron detector (Gatan) in the Purdue Life Science Cryo-EM Facility. A dataset containing ~4587 images was collected in super-resolution mode with a pixel size of 0.539 Å, at a defocus range of 1–3 μm using EPU. For each movie stack, 40 frames were recorded at a frame rate of 78 ms per frame and a total dose of 53.43 electrons/Å2.

Data processing

Request a detailed protocol

Micrographs were motion aligned and motion corrected using motioncor2 (Zheng et al., 2017) implemented within CryoSPARC (Punjani et al., 2017). CTF estimations were completed using CTFfind4 (Rohou and Grigorieff, 2015).

Particle picking, 2D classifications, initial model generation, 3D classification, and refinement were all performed using CryoSPARC. Workflows for each data set are shown in Figure 1—figure supplements 4 and 5. The nominal resolution was determined based on a Fourier shell correlation cutoff of 0.143.

Model building and refinement

Request a detailed protocol

Crystal structures of Gβγ and PLCβ3 (PDB IDs 1GP2 and 4GNK, respectively Lyon et al., 2013; Wall et al., 1995) were rigid-body fit into the cryo-EM map using Chimera (Pettersen et al., 2004). The model was then refined using molecular dynamic flexible fitting (MDFF)(Trabuco et al., 2009). MDFF configuration files were generated using VMD. During MDFF simulation, Gβγ was set as rigid with domain restraints. The MDFF simulation was conducted with a grid scaling value of 0.5 for 100 ps, followed by 3000 steps of energy minimization until convergence of the protein RMSD. The MDFF generated model was inspected and manually adjusted in COOT (Casañal et al., 2020), guided by the use of deep-learning-based amino-acid-wise model quality (DAQ) scoring (Terashi et al., 2023; Terashi et al., 2022) and refined in PHENIX (Adams et al., 2010). Resulting models were assessed in PHENIX for stereochemical correctness. Maps, half maps, and coordinate files were deposited in the PDB as 9Y7H, 9YAO, and 9YAP and in the EMDB as EMD-72655, EMD-72732, and EMD-72733.

Activity assays

Inositol phosphate accumulation

Request a detailed protocol

COS-7 cells were seeded in 12-well culture dishes at a density of 100,000 cells per well and maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (Atlanta Bio), 1 X Glutamax (Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin (Corning) at 37 °C and 5% CO2. Cells were transfected with 400 ng of PLCβ3 variant and 200 ng G protein subunit using Fugene 6 (Promega) at a 3:1 ratio per manufacturer’s protocol. Total DNA varied from 700 to 900 ng per well, with pCMV used as an empty vector. 18–24 hr after transfection, the media was changed to low-inositol Ham’s F-10 medium (Gibco) containing 1.5 μCi/well myo-[2-3H(N)] inositol (Perkin Elmer) for 16–18 hr, then treated with 10 mM LiCl for 1 hr to inhibit endogenous inositol phosphatases. Media was aspirated, cells were washed twice with PBS, and then lysed by addition of ice-cold 50 mM formic acid. Lysates containing [3H]-IPs were applied to Dowex AGX8 columns to isolate the IP species. Columns were washed twice with 10 CVs of 50 mM formic acid, then 100 mM formic acid, and eluted with three CVs of 1.2 M ammonium formate into scintillation vials containing scintillation fluid and counted.

Western blotting

Request a detailed protocol

Cells were lysed in SDS sample buffer (100 mM Tris pH 6.8, 6% sucrose, 2% SDS, 715 mM β-mercaptoethanol, and 0.02% bromophenol blue), boiled, and run on a 10% (w/v) SDS–polyacrylamide gel. Proteins were transferred to PDVF for 16 hr at 25 V, followed by incubation with an antibody against PLCβ3 (Cell Signaling Cat: D9D6S) (1:1000), Gβ1 (Thermo: Cat: PA530046), or actin (Cell Signaling: 8H10D10) (1:2000). Goat anti-rabbit HRP or goat anti-rabbit AlexaFluor 800 antibodies (1:10,000) were added before visualizing with ECL reagent (Pierce) for HRP linked antibodies. Western blots were imaged with a GeneGnome imaging system or Azure Sapphire FL, respectively.

Liposome-based activity assay

Request a detailed protocol

Hen egg white phosphatidylethanolamine (PE) at 100 μM and soy phosphatidylinositol (PI) at 250 μM (Avanti Polar Lipids) were resuspended in CHCl3, mixed, and dried in 312 μL aliquots in borosilicate glass tubes under N2, sealed and stored at –20 °C until use. To prepare liposomes, the lipids were resuspended in 312 μL of sonication buffer (50 mM HEPES pH 7, 80 mM KCl, 2 mM EGTA, and 1 mM DTT) and incubated at room temperature for 5 min, then sonicated to clarity in 30 second duty cycles using a bath sonicator (Avanti Polar Lipids). Each reaction mixture contained 10 μL of liposome solution, 10 μL of PLC solution (50 mM HEPES pH 7, 3 mM EGTA, 80 mM KCl, 3 mM DTT, and 3 mg/mL BSA), 5 μL of Gβγ solution or buffer (50 mM HEPES pH 7, 100 mM NaCl, 5 mM MgCl, 1 mM DTT, and 3 mM EGTA), and 5 μL of CaCl2 solution (50 mM HEPES pH 7, 3 mM EGTA, 80 mM KCl, 1 mM DTT, and 18 mM CaCl2). CaCl2 solution was added last to initiate PI hydrolysis upon transfer to 30 °C, and incubated for 15 min. Control reactions contained all components except CaCl2. Reactions were terminated by the addition of an ice-cold quench solution (50 mM HEPES pH 7, 80 mM KCl, 210 mM EGTA, and 1 mM DTT) and incubated on ice.

IP was quantified using a modified version of the CisBio IP-One Gq assay kit. Following termination, 14 μL of each reaction mixture, 3 μL of d2-labeled IP1, and 3 μL of the cryptate-labeled anti-IP1 antibody (CisBio) were added to a 384-well low-volume white microplate at room temperature (Corning, Corning, NY). Positive controls contained assay buffer, d2-labeled IP1, and cryptate-labeled anti-IP1, and negative controls contained assay buffer, lysis and detection buffers, and cryptate-labeled anti-IP1. The plate was centrifuged at 1000 × g for 1 min, incubated at room temperature for 1 hr, and fluorescence read on a SynergyNeo2 plate reader (BioTek). The concentration of IP1 was calculated from a standard curve and normalized following the manufacturer’s protocol (CisBio).

BRET

Request a detailed protocol

For Venus-Gβγ interaction experiments, HEK 293 cells were transfected with 0.01 μg HiBit-PLCβ, 0.1 μg CMV-LgBit, 0.4 μg Gαq, 0.3 μg Venus-1–155-Gγ2, 0.3 μg Venus-155–239-Gβ1, and 0.3 μg SNAPf-AGTR1. For Gαq-Venus interaction experiments, Gαq-Venus replaced Gαq, and unlabeled Gβ1 and Gγ2 replaced their Venus-labeled counterparts. For PI(4,5)P2 hydrolysis assays, HEK 293 cells were transfected with 0.01 μg Nluc-PH, 0.1 μg SNAPf-AGTR1, and 0.8 μg of mem-link-Venus. For PI(4,5)P2 hydrolysis reconstitution assays, ΔPLC cells were transfected with the same components plus 0.01 μg of HiBit-PLCβ, HiBit-PLCβ-CAAX, or variants thereof. To sequester either active Gαq or Gβγ, GRK2RH or GRK3ct were added at 0.2 μg per well, respectively. For translocation bystander BRET experiments, HEK 293 cells were transfected with 1 μg mem-link-Venus, 0.1 μg CMV-LgBiT, 0.3 μg SNAPf-AGTR1, 0.4 Gαq μg and 0.01 μg HiBit-PLCβ or variant. For all experiments, cells were washed and resuspended in Dulbecco’s phosphate buffered saline (DPBS) and distributed to 96-well plates in suspension immediately before taking BRET measurements. All BRET measurements were made in the presence of furimazine (Promega or ChemShuttle; 1:1000 as supplied or from a 5 mM stock dissolved in 90% ethanol/10% glycerol). BRET and luminescence measurements were made using a Polarstar Optima or Lumistar Omega plate reader (BMG Labtech); angiotensin II was injected from a 10-fold concentrated solution. Raw BRET signals were calculated as the emission intensity at 520–545 nm divided by the emission intensity at 475–495 nm. Net BRET signals were calculated as the raw BRET signal minus the raw BRET signal measured from cells expressing only the donor.

Statistical analysis

Request a detailed protocol

All analysis was carried out using GraphPad Prism Version 10.5.0.

Data availability

All study data are included in the article and/or supporting information. All unique materials produced for this study are available from the corresponding author upon request. Assay data, SDS-PAGE, and western blots are available the Purdue University Research Repository under DOI https://doi.org/10.4231/EK7T-RT26. Maps, half maps, and coordinate files were deposited in the PDB as 9Y7H, 9YAO, and 9YAP and in the EMDB as EMD-72655, EMD-72732, and EMD-72733.

The following data sets were generated
    1. Fisher IJ
    2. Lyon AM
    (2026) Purdue University Research Repository
    Gβγ engages PLCβ3 at multiple sites to reorient and facilitate its activation.
    https://doi.org/10.4231/EK7T-RT26
    1. Fisher IJ
    2. Lyon AM
    (2026) Worldwide Protein Data Bank
    Gbg crosslinked to PLCb3 - second conformation.
    https://doi.org/10.2210/pdb9YAO/pdb
    1. Fisher IJ
    2. Lyon AM
    (2026) Worldwide Protein Data Bank
    Gbg crosslinked to PLCb3 - second conformation.
    https://doi.org/10.2210/pdb9YAP/pdb
    1. Fisher IJ
    2. Lyon AM
    (2026) Electron Microscopy Data Bank
    ID EMD-72655. Gb1g2 crosslinked to PLCb3.
    https://www.ebi.ac.uk/emdb/EMD-72655
    1. Fisher IJ
    2. Lyon AM
    (2026) Electron Microscopy Data Bank
    ID EMD-72732. Gbg crosslinked to PLCb3 - second conformation.
    https://www.ebi.ac.uk/emdb/EMD-72732
    1. Fisher IJ
    2. Lyon AM
    (2026) Electron Microscopy Data Bank
    ID EMD-72733. Gbg crosslinked to PLCb3 - second conformation.
    https://www.ebi.ac.uk/emdb/EMD-72733

References

    1. Lee CW
    2. Park DJ
    3. Lee KH
    4. Kim CG
    5. Rhee SG
    (1993a)
    Purification, molecular cloning, and sequencing of phospholipase C-beta 4
    The Journal of Biological Chemistry 268:21318–21327.
    1. Lee CW
    2. Lee KH
    3. Lee SB
    4. Park D
    5. Rhee SG
    (1994)
    Regulation of phospholipase C-beta 4 by ribonucleotides and the alpha subunit of Gq
    The Journal of Biological Chemistry 269:25335–25338.
    1. Smrcka AV
    2. Sternweis PC
    (1993)
    Regulation of purified subtypes of phosphatidylinositol-specific phospholipase C beta by G protein alpha and beta gamma subunits
    The Journal of Biological Chemistry 268:9667–9674.

Article and author information

Author details

  1. Isaac J Fisher

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing
    Contributed equally with
    Kanishka Senarath
    Competing interests
    No competing interests declared

  2. Kanishka Senarath

    Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United States
    Contribution
    Data curation, Formal analysis, Validation, Investigation, Visualization, Writing – review and editing
    Contributed equally with
    Isaac J Fisher
    Competing interests
    No competing interests declared

  3. Kennedy Outlaw

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Formal analysis, Investigation, Visualization
    Competing interests
    No competing interests declared

  4. Kaushik Muralidharan

    1. Department of Biological Sciences, Purdue University, West Lafayette, United States
    2. Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, United States
    Contribution
    Data curation, Validation, Investigation, Visualization, Writing – review and editing
    Competing interests
    No competing interests declared

  5. Elisabeth E Garland-Kuntz

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Validation, Visualization, Writing – review and editing
    Competing interests
    No competing interests declared

  6. Michelle M Van Camp

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Validation, Investigation
    Competing interests
    No competing interests declared

  7. Thomas Komay

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  8. Leon F Laskowski

    James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    Contribution
    Investigation, Visualization
    Competing interests
    No competing interests declared

  9. Asuka Inoue

    1. Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
    2. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Contribution
    Validation, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  10. Evi Kostenis

    Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
    Contribution
    Validation, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8284-5514

  11. Nevin A Lambert

    Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Project administration, Writing – review and editing
    Competing interests
    Reviewing editor, eLife
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7550-0921

  12. Angeline M Lyon

    1. James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, United States
    2. Department of Biological Sciences, Purdue University, West Lafayette, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Writing – original draft, Project administration
    For correspondence
    lyonam@purdue.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7501-0148

Funding

Japan Society for the Promotion of Science (JP24K21281)

  • Asuka Inoue

Japan Society for the Promotion of Science (JP25H01016)

  • Asuka Inoue

Japan Science and Technology Agency (JPMJFR215T)

  • Asuka Inoue

Japan Science and Technology Agency (JPMJMS2023)

  • Asuka Inoue

Japan Agency for Medical Research and Development (JP22ama121038)

  • Asuka Inoue

Japan Agency for Medical Research and Development (JP22zf0127007)

  • Asuka Inoue

Uehara Memorial Foundation

  • Asuka Inoue

Deutsche Forschungsgemeinschaft (214362475/GRK1873/3)

  • Evi Kostenis

National Heart Lung and Blood Institute (1R01HL141076)

  • Angeline M Lyon

National Institute of General Medical Sciences (F32GM145110-01)

  • Isaac J Fisher

National Institute of General Medical Sciences (R35GM145284)

  • Nevin A Lambert

National Institute of General Medical Sciences (1R01GM152701)

  • Angeline M Lyon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Steve Wilson and Drs. John JG Tesmer, Val J Watts, Thomas Klose, and Frank Vago for technical and conceptual assistance. AI was funded by Japan Society for the Promotion of Science (JP24K21281 and JP25H01016); Japan Science and Technology Agency (JPMJFR215T and JPMJMS2023); Japan Agency for Medical Research and Development (JP22ama121038 and JP22zf0127007); and The Uehara Memorial Foundation. EK was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) with the grant 214362475/GRK1873/3. This work is supported by F32GM145110-01 to IJF, R35GM145284 to NAL, 1R01HL141076 and 1R01GM152701 to AML.

Version history

  1. Sent for peer review:
  2. Preprint posted:
  3. Reviewed Preprint version 1:
  4. Reviewed Preprint version 2:
  5. Version of Record published:

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.110382. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2026, Fisher, Senarath et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 689
    views
  • 37
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Citations by DOI

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Isaac J Fisher
  2. Kanishka Senarath
  3. Kennedy Outlaw
  4. Kaushik Muralidharan
  5. Elisabeth E Garland-Kuntz
  6. Michelle M Van Camp
  7. Thomas Komay
  8. Leon F Laskowski
  9. Asuka Inoue
  10. Evi Kostenis
  11. Nevin A Lambert
  12. Angeline M Lyon
(2026)
Gβγ engages PLCβ3 at multiple sites to reorient and facilitate its activation
eLife 15:RP110382.
https://doi.org/10.7554/eLife.110382.3

Share this article

https://doi.org/10.7554/eLife.110382

Categories and tags

Research organism